That`s right,and that`s exactly why the company would never go for it for less than 120.00 a share. The Lm platform alone will be worth billions,then add the NEO and the HOT and the Her2,and the Petx,and the approved lab/facility. Get out your calculator and divide 8-10 billion by the 41 million float,and you`ll see what we`re worth after Eu approval,and maybe even before,because it`s a slam dunk for Adxs,and IMO,so is the FDA,it`ll just take another year after,and by that time we`ll probably be sold. So the cheapest I see us going for is 4-5 billion,and that`s before approval in the EU. After approval the number doubles again to 240-300 a share. People always forget that the float is so small here,after the monster reverse split that most of us lived through,,125 for 1 share,,it was brutal but it left a very small float,and a potentially huge buyout number. We have less than a year,IMO before EU approval,so dilution is`nt gonna happen,more likely Her2 will be licensed to Merck for Breast cancer,because they need it now,and that money will carry us through to approval,and then we`ll see the big buyout number off of our small float. GLTAL.
News 
Market Data 
Discover 
